2 07, 2024

Volkswagen is Investing Billions into Rivian: Why You Should Invest in RIVN, Too

By |2024-07-02T17:30:57+00:00July 2nd, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

All eyes are on Volkswagen and Rivian right now, as just last week the two automakers teamed up to create an EV-focused joint venture. Volkswagen will gain access to Rivian’s EV technology and a heap of Rivian stock (RIVN) in exchange for up to a $5 billion investment. Shares of RIVN are up 30% [...]

27 06, 2024

Micron Tech Tumbles 6% on Less Than Fantastic Forecast: 3 Reasons It’s STILL Time to Buy MU

By |2024-06-27T17:45:34+00:00June 27th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Micron Tech (MU) reported its fiscal Q3 earnings results alongside a forecast for the final quarter of the fiscal year, and shares slid 6% as investors were expecting more. Revenue came in at $6.81 billion for the quarter, which was a whopping 81% improvement year over year. Analysts were expecting $6.61 billion.  Meanwhile, earnings [...]

26 06, 2024

FedEx Cost Cuts and Upbeat Outlook Send Shares 14% Higher: 3 Other Reasons to BUY FDX

By |2024-06-26T18:15:27+00:00June 26th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

It had been a tough past few months for FedEX (FDX) investors, who watched their positions plummet 14%. But shares have recovered all that and more today after the delivery company released positive 4th quarter results for fiscal 2024. Earnings came in at $5.94 per share, which was ahead of the analyst expectation of [...]

21 06, 2024

Sarepta Shoots up 36% on New Drug Breakthrough for DMD: 2 Reasons to Consider Buying SRPT

By |2024-06-21T17:20:17+00:00June 21st, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

Sarepta Therapeutics (SRPT) announced late Thursday it had gained FDA approval for its treatment designed to target a rare genetic disease known as Duchenne muscular dystrophy (DMD). This condition causes progressive weakness, predominantly in boys, and is caused by a lack of key protein dystrophin. It has no known cure at this time. The [...]

19 06, 2024

Dell Was Down After Disappointing Earnings, But the Road to Recovery is Underway: Time to Buy?

By |2024-06-19T17:32:29+00:00June 19th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Just last month Dell Technologies (DELL) reported first-quarter earnings that fell short of Wall Street’s expectations, taking the stock down from its all-time high of $179/share. It fell more than 30% in just a few days, eroding market cap and scaring investors out of their positions.  The issue was that despite AI growth fueling [...]

18 06, 2024

La-Z-Boy Climbs 17% After Beating Q4 Earnings, Raising Q1 Outlook: Why it May Be Time to Buy LZB

By |2024-06-18T16:55:02+00:00June 18th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , , , , |

Shares of La-Z-Boy (LZB) are up nearly 18% so far Tuesday morning on the heels of its fiscal fourth-quarter results and preliminary first-quarter guidance. The furniture company’s results for the quarter ending April 27th surpassed analyst expectations on both the top and bottom lines.  Adjusted earnings came in at $0.95 per share ahead of [...]

17 06, 2024

Autodesk Investors Can Rest Easy as Financial Investigation is Over: ADSK is Up 5% on the News

By |2024-06-17T16:21:08+00:00June 17th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

Autodesk (ADSK) investors have been anxiously awaiting an update since April 1 of this year after the company became aware of potential discrepancies in its free cash flow and non-GAAP operating margin practices.  This led to the delay of its 10-K for fiscal year 2023 pending a full investigation into the issue, resulting in [...]

13 06, 2024

Broadcom Stock Jumps 13% on 10-for-1 Stock Split: 3 Other Reasons to BUY AVGO Today

By |2024-06-13T17:26:04+00:00June 13th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

While all eyes are on stocks like NVDA, META, GOOG, and other companies staking their claims in the AI race, not enough emphasis has been placed on Broadcom (AVGO). The semiconductor and infrastructure manufacturer is well positioned to profit from this emerging technology. In fact, the company delivered second-quarter results yesterday and reported $3.1 [...]

12 06, 2024

Apple Shares Climb to All-Time High After Latest Tech Update: Is it Time to BUY AAPL, Though?

By |2024-06-14T10:47:32+00:00June 12th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

Yesterday, Apple (AAPL) gained more than 5% to take shares to as high as $207, crossing the $200 threshold for the first time ever. They’ve picked up where they left off today, up another 5% for more than 11% on the week. The stock is currently sitting at $217/share. All this comes after the [...]

10 06, 2024

Should You Buy CrowdStrike After Q1 Revenue and EPS Growth Send Shares 9% Higher?

By |2024-06-10T17:23:23+00:00June 10th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

CrowdStrike (CRWD) is up 9% to start the week after delivering strong first-quarter earnings on the top and bottom lines. The stock is now up 154% in the past year and 51% through 2024 thus far. The cybersecurity company reported a 33% growth in revenue to $921 million, easily surpassing the forecast it set [...]

Go to Top